
Innovative Formulation Developer
Recently, Haichang Biotech announced the appointment of Dr. Xiaofeng Meng as Co-President.Fully responsible for the company's production, quality, registration, and sales operations management.Dr. Meng, with his profound professional background, exceptional leadership, and global perspective, will lead Haichang Biotech to achieve more significant breakthroughs and accomplishments in the field of complex injectable internationalization.

E.N.D

Previous article recommendations:
Innovent Biologics Announces the Appointment of Dr. Su-Hua Zhang as Global Chief Business Officer
Shenzhen Establishes Synthetic Biology Industry Fund with Investment of 1.5 Billion Yuan
Priced at $3.5 Million, Pfizer's AAV Gene Therapy BEQVEZ Approved by FDA for Market Launch
World's First Non-Viral Vector Gene-Modified TIL Therapy Approved for Clinical Use
17 Times in 8 Years, What Did This Gene Therapy Company Do Right?
Ten Fields Worth Noting in China's Biopharmaceutical Industry for the Next Decade (Order Not Ranked)
The World's First AI-Generated Gene Editor Released
Analysis and Outlook of the Nucleic Acid Drug Industry
Hengrui Medicine Subsidiary's First Gene Therapy Product Approved for Clinical Trials
Fosun Pharma's CAR-T Product Yikaida® Second-Line Indication Included in Shanghai Huibao
Another CAR-T Commercial Production Base Breaks Ground in China
Bi Jingquan: Understanding Innovative Drugs from the Perspective of Innovation and Clinical Value
Global Renowned Investment Bank: It's Time to Invest in Biotechnology